We introduced a normal chromosome 11 into GM979 murine erythroleukemia cells by fusing them with Epstein-Barr virus-transformed lymphocytes from a normal individual. In contrast to previous data obtained with other murine erythroleukemia cells, we detected activation of human chromosomal y-globin genes in GM979 cells. GM979, unlike previously used murine erythroleukemia cell lines, expresses murine embryonic globin in addition to adult globin. While all the hybrids expressed y-and (3-globin, they displayed a wide range of 'y-globin expression in relation to that of 13-globin (13, 14) . Since in this case information was supplied by the incoming chromosome itself, the data argue strongly for two alternative interpretations: either the MEL cells lack transacting factors specific for y-globin activation or normal adult y-globin genes in their chromosomal context are not accessible to transcriptional factors present in MEL cells.
between murine embryonic globin and human y-globin in these hybrids, suggesting that the two globins are regulated independently, at least in this cell line. These data indicate that y-globin genes from normal, nonerythroid chromosomes are not irreversibly silenced, and they can be activated by a positive trans factor(s) present in GM979 cells.
The human f-globin locus on chromosome 11 contains several closely linked genes that are expressed sequentially during development. The e-globin gene is expressed during the embryonic erythropoiesis in yolk sac, the two y-globin genes (Gy and Ay) are expressed primarily in the fetal liver stage of erythropoiesis, and these are replaced by the two adult genes (6 and A) after birth (1) . Studies in transgenic mice have shown that embryonic yolk sac cells provide a competent environment for the expression of normal human fetal globin genes, whereas cells in the fetal liver and adult marrow support expression of adult human genes (2) (3) (4) (5) (6) . These results were interpreted to suggest that differential globin expression is controlled by interactions between DNA sequences in the A3-globin locus and stage-specific trans-acting factors. More recent transgenic experiments in which further upstream sequences and larger fragments of DNA were included have indicated that for proper developmental control, both fetal and adult globin genes need to be present in their natural chromosomal order (7) . Although differences in the complement of transcriptional factors between fetal and adult erythroid cells, allowing a weighted competition between 13 and y expression, offer a reasonable interpretation of these data, stage-specific trans-acting factors in man have not been isolated. Isolation of several erythroid-specific factors has been reported recently, and information about stage-specific or gene-specific factors in other species, however, is beginning to emerge (8, 9) .
In addition to transgenic mice, mouse erythroleukemia (MEL) cells have been used as cellular models to study regulatory mechanisms of globin gene expression. Heterospecific hybrids made from human nonerythroid cells fused with MEL cells express 13-but not y-globin (10) (11) (12) , consistent with the view that MEL cells possess an adult erythroid environment only. However, fetal globin was expressed when chromosomes from fetal erythroid cells or from lymphoid cells carrying HPFH (hereditary persistence of fetal hemoglobin) mutations were introduced into MEL cells (13, 14) . Since in this case information was supplied by the incoming chromosome itself, the data argue strongly for two alternative interpretations: either the MEL cells lack transacting factors specific for y-globin activation or normal adult y-globin genes in their chromosomal context are not accessible to transcriptional factors present in MEL cells.
To test whether nonerythroid 'y-globin genes in their normal chromosomal context could be activated, we fused human lymphoblasts with GM979 cells, a MEL cell line that coexpresses murine embryonic (eY) and adult (j8maj) globins (15) (16) (17) . Because GM979 cells express murine embryonic globins and because human y genes are preferentially expressed in murine embryonic cells (5, 6), we speculated that GM979 cells might harbor a trans-active environment capable of fetal human globin gene activation. We found that both y-V and j-globin genes were activated in lymphoid-GM979 hybrids, providing evidence for the presence in GM979 cells of positive trans factors for human fetal globin. Branch, Developmental Therapeutics Program, Division of Cancer Treatment, National Cancer Institute, Bethesda, MD) to kill the mouse parental cells, which were APRT-(both MEL179 and GM979 cell lines were APRT-), and ouabain (0.25 tug/ml) to kill the human parental cells (the EBV-transformed lymphoblasts). Only hybrids that had inherited ouabain resistance from the mouse genome and the APRT+ phenotype from the human genome survived. The second method of selection used medium containing G418 (0.14 Ag/ml) to kill the hybrid parental cells (the lymphoid cell-GM979 hybrid that had lost chromosome 11) and ouabain (0.25 Ag/ml) to kill the human parental cells (the neomycin-resistant, EBV-transformed lymphoblasts). Only new hybrids that had inherited ouabain resistance from the genome of the old hybrid and neomycin resistance from the human genome survived. Clonal outgrowths appeared 10 days to 3 weeks after fusion and were subsequently grown in Iscove's modified Dulbecco's medium with 10%o fetal bovine serum not containing any selective chemicals. Cells containing human chromosome 11 were identified by specific binding to the fluorescently labeled monoclonal antibody 53.6 (13). This monoclonal antibody detects a constitutively expressed cell surface antigen whose gene resides on human chromosome 11. Cell populations were enriched for cells expressing the 53.6 antigen (13). Some hybrids were subcloned by limiting dilution at desired times after their selection.
Induction of Hybrids and Assessment of Globin Expression. Hybrid cell populations were "panned" to high levels of positivity for 53.6 (70% or greater) before induction. The cells were induced for 4 days in medium containing either 3 mM hexamethylenebisacetamide (Aldrich) or 0.75 mM butyric acid (Sigma). Globin expression was evaluated at the protein and RNA levels. Protein expression was assessed through the use of our y-and p-chain specific monoclonal antibodies in 60_ direct immunofluorescence assays, as before (13, 21 (25); mouse ey, pSP65ME, with a protected fragment of 145 bp (26) .
RESULTS

Activation of Fetal Globin Genes from Human Lymphoid
Cells. To test whether a normal, silent, y-globin gene of a lymphoid chromosome can be activated in trans, we fused EBV-transformed lymphocytes from a normal individual with GM979 cells. Seven of 52 clonally derived lymphoid-GM979 hybrids retained human chromosome 11 and all expressed both y-and 3-globin as assessed by immunofluorescent labeling using y-or P-chain-specific monoclonal antibodies. At 5-12 weeks after fusion the percentage of human globin-producing cells that were y-globin positive ranged from 0.5% to 88% (Fig. 1) . In a control experiment, EBV-transformed lymphoblasts were fused with MEL179 cells. Seventeen of 152 clonally derived lymphoid-MEL179 hybrids retained human chromosome 11, and 7 were selected for study. Immunofluorescent labeling (Fig. 1) showed that all 7 hybrids expressed f8-globin in a high proportion of cells; (Fig. 2) . Lymphoid-GM979 hybrid 52, in which 88% of human globin-producing cells were ypositive, contained predominantly 'y-globin mRNA, while there was only (3-globin mRNA in lymphoid-MEL179 hybrids that expressed no y-globin by immunofluorescence.
Subcloning. To assess the heritability of the y-positive phenotype seen in our lymphoid-GM979 hybrid cell populations, we subcloned hybrids with high or low 'y expression (Fig. 1) . From hybrid 52, a high V-expressing hybrid, 14 subclones were tested (Fig. 1) . Twelve subclones expressed -globin in 79-98% of human globin-expressing cells, thus closely resembling the phenotype of the parental hybrid; 2 subclones expressed y-globin in only 0.5-1% of human globin-expressing cells. However, in secondary and tertiary subclonings the proportions of subclones with low or no y-globin expression increased. Subclones from a low -expressing hybrid (Fig. 1) had either low or no y expression. Selected subclones were analyzed by RNase protection (Fig.  2) . Subclone 52-15, in which 98% of human globin-expressing cells were y-positive, expressed predominantly y mRNA. embryonic globin ey. Surprisingly, the APRT-GM979 line used in these fusions also displayed strikingly low Ey-globin mRNA compared with the parental GM979 cells (Fig. 3) . The APRT-GM979 line may have lost the potential for high embryonic globin expression as a consequence of mutagenesis or because the APRT-mutation happened to occur in a GM979 cell with low embryonic globin expression. In spite of the low ey-globin expression, however, this line retained trans-acting factors capable of activating the human y genes.
Refusion Experiments. To test whether the lymphoid-GM979 hybrids that had lost, after subcloning, y-globin expression had also lost their trans-acting factors that activate the y-globin genes, refusion experiments were done with the following rationale. If a hybrid loses y-globin expression because of loss of the GM979 y-globin-activating factor, this hybrid should be unable to activate y-globin in a newly introduced chromosome 11. On the other hand, if the transacting environment that induces y-globin is still present in the hybrid that has lost -t-globin expression, then that hybrid should be able to activate the y gene of a new chromosome 11 introduced by cell fusion. To test these possibilities the strategy outlined in Fig. 4 was used. A lymphoid-GM979 hybrid expressing only P3-and no -globin was allowed to lose human chromosome 11, so that a chromosome 11-negative hybrid was produced. To this hybrid a new human chromosome 11 was introduced by fusion with EBV-transformed lymphoblasts. We then asked whether the y genes of the newly introduced chromosome 11 were activated or not. To do this experiment we selected a subclone of hybrid 52, which expresses only /3-globin (Fig.  SB) . Populations of hybrid cells without chromosome 11 were isolated by their failure to adhere to plates coated with the monoclonal antibody 53.6 and further subcloned to secure absence of chromosome 11. As expected, the isolated clones expressed neither y-nor (-globin as assessed by monoclonal antibody labeling (Fig. SC) and by RNase protection. Due to the design of our original fusion of human lymphoblasts with GM979 cells the human chromosome 11-negative hybrids were both ouabain-resistant and APRT-positive. In order to fuse human lymphoblasts with such hybrids, we needed to introduce a new, selectable trait into the human lymphoblasts, neomycin resistance (see Materials and Methods). Neomycin-resistant, ouabain-sensitive human lymphoblasts were then fused with neomycin-sensitive, ouabain-resistant, chromosome 11-negative hybrids. After the second fusion, medium containing both G418 and ouabain ensured that only those hybrids that were the product of the second fusion would survive.
Ninety-four clones were tested for the presence of human chromosome 11; two chromosome 11-containing hybrids were isolated. In these hybrids a new human chromosome 11 must have been introduced into the human lymphoid-(chromosome 11-negative)-GM979 hybrid cell. Human globin expression was tested 6 weeks after fusion. Both hybrids expressed fetal human globin as assessed by monoclonal antibody labeling (Fig. SD) and RNase protection (data not shown). Twenty-five and 41% of the human globinexpressing cells of the two hybrids were producing y-globin.
DISCUSSION
Previously made hybrids between MEL cells and human nonerythroid (lymphoid or fibroblastic) cells expressed f-but not y-globin (10) (11) (12) , suggesting that MEL cells contain trans factors that support the preferential expression of human genes when both (3 and y genes are present in their normal chromosomal location. GM979, the MEL line used in the present studies, expresses embryonic murine globin in addition to adult globin. If the silent y-globin genes of lymphoid cells can be reactivated, and if the murine embryonic factors present in the GM979 cells can interact with the human -globin genes, then lymphoid GM979-hybrids should express human y-globin. We found abundant y-globin expression in the majority of our human lymphoid-GM979 hybrids, providing formal evidence that GM979 cells contain trans factors that can activate the chromosomal human y-globin genes from nonerythroid cells.
The proportion of cells expressing y-globin varied widely from hybrid to hybrid. However, this variation was not related to differences in the expression of embryonic globins by the endogenous murine genes, suggesting that human fetal and murine embryonic globin genes may be independently regulated. Heterogeneity in the y-globin phenotype of lymphoid-GM979 hybrids could be explained by several mechanisms. cause it requires segregation, from the y-negative hybrids, of both murine homologues containing the y-gene activator. Against this possibility is also the fact that human-murine cell hybrids preferentially segregate human, rather than murine, chromosomes. (ii) Heterogeneity could be due to variation in the abundance of the y-globin activating factor among GM979 cells. Evidence against this mechanism was obtained from refusion experiments showing that a lymphoid-GM979 subclone that previously expressed only P-globin was still able to transactivate the y-globin genes of a newly introduced human chromosome 11. However, whether the y-globin activating factor existed in the "recycled" GM979 cells before fusion or was synthesized de novo after refusion was not addressed by these experiments. (iii) Heterogeneity may reflect variation in the presence of human chromosomes other than chromosome 11. This hypothesis implies that the synergistic action of two factors, one derived from the murine genome (27) , the validity of this assumption clan be tested by introducing a single chromosome 11 into GM979 cells through microcell fusion. Finally, it is theoretically possible that within the hybrid cells the y gene, in contrast to the f3 gene, is prone to cis changes, some time after fusion, leading to its silencing even in the presence of the trans factors that yielded its initial activation.
